Hypertension is considered as a low-grade inflammatory disease, with adaptive immunity being an important mediator of this pathology. TLR4 may have a role in the development of several cardiovascular diseases; however, little is known about its participation in hypertension. We aimed to investigate whether TLR4 activation due to increased activity of the reninangiotensin system (RAS) contributes to hypertension and its associated endothelial dysfunction. For this, we used aortic segments from Wistar rats treated with a non-specific IgG (1 mg/day) and SHRs treated with losartan (15 mg/kg?day), the non-specific IgG or the neutralizing antibody anti-TLR4 (1 mg/day), as well as cultured vascular smooth muscle cells (VSMC) from Wistar and SHRs. TLR4 mRNA levels were greater in the VSMC and aortas from SHRs compared with Wistar rats; losartan treatment reduced those levels in the SHRs. Treatment of the SHRs with the anti-TLR4 antibody: 1) reduced the increased blood pressure, heart rate and phenylephrine-induced contraction while it improved the impaired acetylcholineinduced relaxation; 2) increased the potentiation of phenylephrine contraction after endothelium removal; and 3) abolished the inhibitory effects of tiron, apocynin and catalase on the phenylephrine-induced response as well as its enhancing effect of acetylcholine-induced relaxation. In SHR VSMCs, angiotensin II increased TLR4 mRNA levels, and losartan reduced that increase. CLI-095, a TLR4 inhibitor, mitigated the increases in NAD(P)H oxidase activity, superoxide anion production, migration and proliferation that were induced by angiotensin II. In conclusion, TLR4 pathway activation due to increased RAS activity is involved in hypertension, and by inducing oxidative stress, this pathway contributes to the endothelial dysfunction associated with this pathology. These results suggest that TLR4 and innate immunity may play a role in hypertension and its associated end-organ damage.
Introduction
Hypertension has been generally associated with structural and functional vascular alterations, and both endothelial dysfunction and increased vasoconstrictor responses are important features of this pathology. The reduced nitric oxide (NO) bioavailability caused by increased reactive oxygen species (ROS) production would explain these vascular alterations. In this context, in recent years, it has been proposed that low-grade inflammation plays a key role in the development and progression of hypertension [1] [2] [3] [4] . Indeed, in hypertension, increases in the plasma levels of proinflammatory cytokines [1] , in the ROS production [5, 6] and in the vascular responses to lipopolysaccharide (LPS) [7] [8] [9] have been observed. It is worth noting that inflammation also induces endothelial dysfunction in humans and animals [9, 10] . Increased activation of the renin-angiotensin system (RAS) seems to be associated with the inflammatory state observed in hypertension, as well as with its associated vascular alterations [1, 5, 11, 12] . Angiotensin II (Ang II), the effector peptide of RAS, is able to induce Toll-like Receptor 4 (TLR4), and it seems that TLR4-dependent signaling pathway contributes to the proinflammatory effects of this humoral factor [13] [14] [15] [16] [17] [18] [19] .
TLRs belong to a large family of pattern recognition receptors that play important roles in mammalian defense systems against invading microorganisms. Among then, TLR4 is expressed on the surface of several cell types, including endothelial and vascular smooth muscle cells (VSMCs). It recognizes and responds against LPS, the main component of the cell wall of Gram-negative bacteria, as well as other non-infectious compounds, such as the products of tissue death and/or damage (DAMP), heat shock proteins (Hsp), high-mobility group box 1 (HMGB1) protein, fibronectin, heparan sulfate and fibrinogen. After activation, TLR4 can initiate the innate and, subsequently, the adaptive immunity; both mechanisms are responsible for the inflammatory response [20, 21] . It has also been shown that upon TLR4 activation, LPS produces ROS such as superoxide anion and hydrogen peroxide [22] [23] [24] [25] , which also contribute to the inflammatory response.
The roles of the TLR4 signaling pathway in the processes underlying inflammatory vascular diseases including atherosclerosis [14] , diabetes [26] [27] [28] or pre-eclampsia [29, 30] have been reported. While several studies have addressed the contribution of adaptive immunity to the pathophysiology of hypertension, there are few studies regarding the role of the innate immune system in the context of this pathology [31] [32] [33] . Therefore, the aim of this study was to investigate whether TLR4 activation, due to increased RAS activity, contributes to hypertension and the functional vascular alterations observed in this pathology. The specific objectives were to investigate the following: 1) the alteration of TLR4 expression in hypertension and the contribution of Ang II to this alteration; 2) the role of TLR4 in hypertension occurrence, as well as in the associated vascular function alterations; and 3) the involvement of the TLR4-activated ROS production in the vascular dysfunction associated to this pathology. Adults male spontaneously hypertensive (SHRs) and Wistar rats were used for these studies. Rats were housed under a 12 h light/ 12 h dark cycle, they had free access to water and were fed a standard rat chow ad libitum. In one set of experiments, we analyzed if hypertension alters TLR4 expression and its dependence on RAS activity. For this, we used Wistar rats and SHRs untreated and treated with the AT 1 receptor antagonist losartan (15 mg/kg?day in the drinking water, 12 weeks; generously supplied by Merck & Co., Inc., Rahway, NJ, USA). Systolic arterial pressure was measured by tail plethysmography.
Materials and Methods

Ethics statement and Animals
In another set of experiments, we investigated whether the TLR4 receptor plays a role in the occurrence of hypertension and the associated vascular alterations. For this, we used SHRs (258.5610.9 g, n = 10) treated with an anti-TLR4 antibody (rat monoclonal IgG 2a , 1 mg/day saline-diluted, intraperitoneal injection, 15 days; sc-13591, Santa Cruz Biotechnology Inc., Dallas, TX, USA) and Wistar rats (272.1615.7 g, n = 9) and SHRs (245.9612.5 g, n = 9) treated with a non-specific IgG (IgG 2a , Figure 2 . TLR4 inhibition reduces blood pressure and heart rate in hypertensive rats. (A) Systolic blood pressure (SBP), (B) diastolic blood pressure (DBP), (C) mean blood pressure (MBP) and (D) heart rate (HR) in Wistar and SHRs treated with a non-specific IgG (1 mg/day, 15 days) and SHRs treated with anti-TLR4 antibody (1 mg/day, 15 days). The results represent the mean6SEM. *P,0.05 vs Wistar, #P,0.05 vs. SHR using one way ANOVA and Bonferroni post-test. n = 8-9. doi:10.1371/journal.pone.0104020.g002 1 mg/day, saline-diluted, intraperitoneal injection, 15 days; sc-2026, Santa Cruz Biotechnology Inc.) to rule out non-specific effects of the anti-TLR4 antibody treatment [32] . Hemodynamic parameters and vascular function in aortic rings were evaluated. To further elucidate the role of TLR4 in the Ang II effects, cell culture experiments using VSMCs from Wistar and SHR were used.
Rats were euthanized by CO 2 , and all efforts were made to minimize suffering. Then, the aortas were removed and placed in cold (4uC) Krebs-Henseleit solution (KHS) (115 mM NaCl, 25 mM NaHCO 3 , 4.7 mM KCl, 1.2 mM MgSO 4 .7H 2 O, 2.5 mM CaCl 2 , 1.2 mM KH 2 PO 4 , 11.1 mM glucose, and 0.01 mM Na 2 EDTA) aerated with a 95% O 2 -5% CO 2 mixture (pH = 7.4). Aortic segments were dissected free of fat and connective tissue and maintained in KHS. Segments used for gene expression studies were immediately frozen in liquid nitrogen and kept at 270uC until the day of the experiment. The hearts were removed to assess cardiac hypertrophy. For this, the ratio between the heart dry weight and the length of the tibia was calculated. 
Hemodynamic parameters
At the end of the treatment, body weight was recorded and the rats were anesthetized with urethane (4 g/kg of body weight, intraperitoneal injections). The right coronary artery was cannulated with a heparinized polyethylene catheter (PE-50) and connected to a data acquisition system with pressure transducers (TSD 104A, Biopac Systems, Inc., Goleta, CA, USA) to measure hemodynamic parameters. Following an adaptation period of 30 min, systolic, diastolic, mean blood pressure and heart rate (SBP, DBP, MBP and HR, respectively) measurements were recorded.
Vascular function
Vascular function was studied in aortic segments by isometric tension recording using an isometric force transducer (TSD 125C) connected to an acquisition system (Biopac Systems, Inc.). Segments were initially exposed to 75 mM KCl to test their functional integrity, and the presence of endothelium was confirmed by the effect of 10 mM acetylcholine in segments that previously contracted with 1 mM phenylephrine. After a washout period, a single concentration-response curve to phenylephrine (0.1 nM-0.3 mM) or acetylcholine (0.01 nM-0.3 mM) was performed. Thus, parallel experiments in different aortic segments from the same animal were performed in the absence (control) and the presence of the NAD(P)H oxidase inhibitor apocynin (30 mM), Figure 5 . TLR4 inhibition abolishes the inhibitory effect of antioxidants on phenylephrine-induced contraction. Concentrationresponse curves to phenylephrine in aortic segments from Wistar and SHRs treated with a non-specific IgG (1 mg/day, 15 days) and SHRs treated with anti-TLR4 antibody (1 mg/day, 15 days) in the absence and presence of (A) tiron (1 mM), (B) apocynin (30 mM) and (C) catalase (1000 U/ml). Control curves were the same in the different situation of the three experimental groups. The results are the mean6SEM. *P,0.05 vs. SHR using two-way ANOVA and Bonferroni post-test. The number of animals used is shown in parentheses. doi:10.1371/journal.pone.0104020.g005 the superoxide anion scavenger 4, 5-dihydroxy-1, 3-benzenedisulphonic acid (tiron, 1 mM) and the hydrogen peroxide detoxificant catalase (1000 U/ml). These drugs were administered 30 min prior to incubation with phenylephrine or acetylcholine.
The influence of endothelium on the response to phenylephrine was investigated after mechanical removal of this vascular component by rubbing the lumen with a needle. The absence of endothelium was confirmed by the inability of 10 mM acetylcholine to produce relaxation. To evaluate the NO component of the phenylephrine responses, the aortic rings were half-maximally precontracted with 1 mM phenylephrine for 30 min; then, a nonselective inhibitor of NO synthesis, N G -nitro-L-arginine methyl ester (L-NAME, 100 mM), was added for 45 min. The results of Figure 6 . TLR4 inhibition abolishes the enhancing effect of antioxidants on acetylcholine-induced vasodilation. Concentrationresponse curves to acetylcholine in aortic segments Wistar and SHRs treated with a non-specific IgG (1 mg/day, 15 days) and SHRs treated with anti-TLR4 antibody (1 mg/day, 15 days) in the absence and presence of (A) tiron (1 mM), (B) apocynin (30 mM) and (C) catalase (1000 U/ml). Control curves were the same in the different situation of the three experimental groups. The results are the mean6SEM. *P,0.05 vs. SHR using two-way ANOVA and Bonferroni post-test. The number of animals used is shown in parentheses. doi:10.1371/journal.pone.0104020.g006 the additional tone caused by L-NAME were expressed as the % of the previous contraction elicited by phenylephrine [34] .
Immunofluorescence TLR4 was immunolocalized as described [12] . Briefly, frozen transverse sections (14 mm) were cut on to gelatin coated slides and air-dried for at least 60 min. After blockade, sections were incubated with a polyclonal antibody against TLR4 (1:100, Santa Cruz Biotechnology, Inc.) in PBS containing 2% bovine serum albumin (BSA, Sigma Chemical Co.) for 1 h at 37uC in a humidified chamber. After washing, rings were incubated with the secondary antibody, a goat anti-rat (1:200) IgG labeled with alexa fluor-546 dye (Molecular Probes Inc., Eugene, OR, USA) for 1 h at 37uC in a humid box. After washing, immunofluorescent signals were viewed using an inverted Leica TCS SP2 confocal laserscanning microscope with oil immersion lens (x40). Alexa Fluorlabeled antibody was visualized by excitation at 546 nm and detection at 550-650 nm. The specificity of the immunostaining was evaluated by omission of the primary antibody and processed as above. Under these conditions, no staining was observed in the vessel wall. Nuclei were stained with 0.01 mg/ml DAPI (Molecular Probes Life Technologies) and visualized with excitation/ emission wavelengths of 358/461 nm.
Cell Culture
To obtain primary cultures of VSMCs, thoracic aortas from SHRs or Wistar rats were aseptically removed, cleaned of fat tissue and blood cells and placed in cold Dulbecco's modified Eagle's medium (DMEM) (Sigma Chemical Co., St. Louis, Mo, USA) containing 0.1% BSA, 200 U/ml penicillin and 200 mg/ml streptomycin. The aortas were digested in the same medium containing 2 mg/ml collagenase type II (Worthington, Lakewood, NJ, USA) and incubated for 30 min at 37uC in a humidified atmosphere of CO 2 (5%). After the adventitia was carefully removed, VSMCs were obtained using the explant method [35] . Cells were identified as VSMCs by morphological and growth characteristics and by positive immunocytochemical staining with a specific monoclonal anti-a-actin antibody (Sigma Chemical Co.). For experiments, cells from passages 2 to 5 were rendered quiescent by incubation in DMEM containing 0.2% FBS for 24 h. The cells were stimulated with 100 nM Ang II (for the times indicated in the results section), with or without pretreatment for 1 h with the TLR4 inhibitor CLI-095 (1 mM). The specificity of CLI-095 was confirmed by its capacity to abolish the induction of COX-2 expression in VSMCs following exposure to LPS (data not shown).
Quantitative PCR real time (qRT-PCR) assay
TLR4, NOX-1, NOX-2, NOX-4 and p22phox mRNA levels were determined in the aortic segments and/or VSMCs by qRT-PCR. Total RNA was obtained using the TRI Reagent (Sigma Chemical Co.), according to the manufacturer's recommendations, and was reverse-transcribed using the High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA). PCR was performed using the fluorescent dye SyBR Green (iTaq FAST SyBR Green Supermix with ROX, Bio-Rad Laboratories, Hercules, CA, USA) or using Taqman Gene Expression Assays (NOX-1: Rn00586652_m1; NOX-4: Rn00585380_m1, Applied Biosystems). The primer sequences used are: TLR4 (FW: TGTGCCTTCAAAACATGACTGG, RV: CTCCCAAGAT-CAACCGATGG); p22phox (FW: GGACAGAAGTACCT-GACCGC, RV: GATGGTGGCCAGCAGGAAG); NOX-2 (FW: CCAGTGAAGATGTGTTCAGCT, RV: GCACAGC-CAGTAGAAGTAGAT). Cyclophilin D (Rn01458749_g1, Applied Biosystems) and b2-microglobulin (Rn00560865_m1, Applied Biosystems) were used as normalizing internal controls. All PCRs were performed in duplicate. qRT-PCR was carried out in an ABI PRISM 7000 Sequence Detection System (Applied Biosystems, from the Centro de Apoyo Tecnológico of URJC) using the following conditions: 2 min at 50uC; 10 min at 95uC; and 40 cycles of 15 s at 95uC and 1 min at 60uC. At the end of the SyBR Green PCR, a final stage with a melting curve analysis was added to show the specificity of the product. To calculate the relative index of gene expression, we employed the 2 2DDCt method using the untreated samples for calibration.
Detection of ROS
The oxidative fluorescent dye dihydroethidium (DHE) was used to evaluate in situ superoxide anion production in VSMCs [35] . Hydroethidine freely permeates cells, and in the presence of superoxide anions it is oxidized to ethidium bromide, which is trapped by intercalation with DNA. Ethidium bromide is excited at 546 nm and has an emission wavelength of 610 nm. Briefly, VSMCs were plated onto glass coverslips placed in 6-well plates and cultured as described above. Subconfluent cells were stimulated with 100 nM Ang II for 2 h in the absence or presence of 1 mM CLI-095, which was added 1 h prior Ang II. The cells were then incubated with 10 mM DHE in cell culture medium for 30 min at 37uC. The images were then acquired using a fluorescence microscope (Nikon Eclipse T300, objective 620, Nikon Corporation, Tokyo, Japan), captured using a digital spot camera (Diagnostic, Spectra Services, Ontario, NY, USA) and processed using the Metamorph image analysis software (Molecular Devices Corp., Downingtown, PA, USA). Non-stimulated VSMCs were imaged daily in parallel, using the same image settings throughout the course of the study. DHE fluorescence was 
NAD(P)H oxidase activity
The superoxide anion generated by NAD(P)H oxidase activity was determined using a chemiluminescence assay using 5 mM lucigenin and 100 mM NAD(P)H. VSMCs treated as described for the ROS detection experiments were homogenized in a lysis buffer (50 mM KH 2 PO 4 , 1 mM ethylene glycol tetraacetic acid, 150 mM sucrose, pH = 7.4). The reaction was initiated with the addition of a mixture of lucigenin and NAD(P)H to the protein sample in a final volume of 300 ml. Chemiluminescence was determined every 2.4 s for 5 min in a plate luminometer (AutoLumat LB 953, Berthold Technologies GmbH & Co. KG, Bad Wildbad, Germany). A buffer blank was subtracted from each reading, and the value of the area under the curve was used to quantify chemiluminescence. The data obtained (counts/s) were expressed as fold increases over the control situation.
In vitro wound healing assay
To verify the role of TLR4 in Ang II-induced migration, a wound healing assay was performed. For this, the cells were seeded and cultured to confluence in a 24-well plate. Then, the cells were switched to serum-free medium for 24 h before the initiation of the experiments. A wound was made with a P10 pipette tip (CRP, with a filter). The medium was changed twice (5 ml/well) to wash away any cell debris remaining in the wound area. A line was drawn through the center of the wells, perpendicular to the wound. A picture was taken at time zero at the site of intersection of the line and the wound. Then, the cells were treated for 1 h with 1 mM CLI-095, followed by 100 nM Ang II. At 24 h, we took a picture in the same location. Adobe Photoshop CS2 was used to determine the area of wound closure compared to time 0 for the stimulus and with respect to the control situation.
Cell proliferation assay
Cell proliferation was assessed using the CellTiter 96 NonRadioactive Cell Proliferation Assay (Promega Corporation, Madison, WI, USA). For this, VSMCs were seeded in 96-well plates (20610 3 cells/well) in DMEM and were allowed to attach for 24-36 h. Then, the cells were switched to serum-free medium for 24 h. After this, cells were treated with 1 mM CLI-095 for 1 h, followed by 100 nM Ang II for 24 h. The proliferative response was quantified by adding MTS tetrazolium solution (20 ml/well). After 2-3 h of incubation, absorbance was measured at 490 nm using a microplate reader (ASYS Hitech GmbH, Eugendorf, Austria). Different assays were performed in triplicate.
Drugs and reagents
l-phenylephrine hydrochloride, acetylcholine chloride, tiron, catalase, apocynin, lucigenin, salts and other reagents were purchased from Sigma Chemical Co. and Merck (Darmstadt, Germany). DHE, streptomycin and penicillin were obtained from Invitrogen (Carslbad, CA, USA), and CLI-095 was obtained from Invivogen (San Diego, CA, USA). All drugs were dissolved in distilled water, except for CLI-095, which was dissolved in 
Statistical analyses
Vasoconstrictor responses induced by phenylephrine were expressed as the % of the tone generated by 75 mM KCl. Vasodilator responses induced by acetylcholine were expressed as the % of the previous tone in each case. The maximum response (Emax) and pD 2 values were calculated by non-linear regression analysis of each individual concentration-response curve using GraphPad Prism Software. To compare the effect of endothelium removal on the response to phenylephrine in segments from the three groups, the results are expressed as the differences of areas under the concentration-response curves (dAUC) in the control and experimental situations. AUCs were calculated from the individual concentration-response curve plots using a computer program (GraphPad Prism Software, San Diego, CA, USA); the differences were expressed as the % of the AUC of the corresponding control situation.
The results are expressed as the mean6SEM (standard error of the mean) of the number of animals or the number of different cultures used in each experiment; differences were analyzed using Students t-test or one-or two-way analyses of variance (ANOVA), followed by the Bonferroni post hoc test, or Mann-Whitney nonparametric test by using GraphPad Prism Software. Differences were considered statistically significant at P,0.05.
Results
Angiotensin II contributes to increased vascular TLR4 gene expression in SHRs
TLR4 mRNA expression was greater in aortic segments from SHRs when compared with those from Wistar rats; this greater expression was reduced after treatment of SHRs with the AT 1 receptor antagonist losartan (Fig. 1A) , which suggests that Ang II contributes to this increased expression. Similarly, TLR4 mRNA levels were greater in VSMCs from SHRs than from Wistar rats (Fig. 1B) .
Immunofluorescence experiments confirm the greater expression of TLR4 in aorta from SHR when compared with Wistar rats; this receptor was localized in the three layers of the vascular wall (Fig. 1C) .
TLR4 inhibition reduces blood pressure and heart rate in hypertensive rats
At the end of the treatment, body weight (Wistar: 322.8610.4 g, n = 7; SHR: 289.867.6 g, n = 9; anti-TLR4 SHRs: 281.5610.7 g, n = 10) and the tibia length (Wistar: 3.860.1; SHR: 3.460.1; anti-TLR4 SHRs: 3.260.1 cm) was similar (P.0.05) in the three animal groups. The heart weight:tibia length ratio was greater in SHRs (0.34660.022) as compared with Wistar rats (0.29460.009), although the differences did not reach statistical significance (P = 0.068); treatment of SHR with anti-TLR4 antibody did not affect this ratio (0.34660.009, P.0.05).
As expected, SHRs have greater levels of SBP, DBP, MBP and HR than Wistar rats ( Fig. 2A-D) . Anti-TLR4 antibody treatment of SHR lowered the SBP, DBP and MBP in SHRs ( Fig. 2A-C) compared with the controls. Additionally, the HR also decreased with treatment (Fig. 2D) .
TLR4 inhibition reduces phenylephrine-elicited vasoconstriction and increases acetylcholine-elicited vasodilation in SHR aortas
The maximum response induced by 75 mM KCl was similar in the aortic rings from both Wistar (1.8760.01 g; n = 8) and SHRs (1.9260.08 g, n = 9; P.0.05). Treatment of SHRs with the anti-TLR4 antibody did not modify KCl response (1.7060.01 g, n = 10; P.0.05). The contraction induced by phenylephrine was greater in aortic segments from SHR when compared with Wistar rats (pD 2 SHR: 6.6960.07 vs. Wistar: 6.5460.11, P.0.05; Emax SHR: 135.768.0% vs. Wistar: 100.369.5%, P,0.05 ; Fig. 3A) ; however, after anti-TLR4 antibody treatment of SHRs the phenylephrine-induced responses were lower (pD 2 SHR anti-TLR4: 6.2260.12, P,0.05 vs. SHR; Emax SHR anti-TLR4: 105.2613.4%, P,0.05 vs. SHR; Fig. 3A) . Furthermore, endothelium-dependent relaxation to acetylcholine was lower in SHRs (pD 2 Fig. 3B ), being these responses increased by the anti-TLR4 antibody treatment (pD 2 : 8.1060.14, P,0.05; Emax: 89.263.3%, P, 0.05; Fig. 3B ).
To evaluate the influence of endothelium in the response to phenylephrine, this layer was mechanically removed. In these conditions, the response to phenylephrine was increased in the three groups (Fig. 4A-C) ; however, this increase was smaller in SHRs, as shown by the analysis of dAUC values, while the anti-TLR4 antibody treatment restored this increase (Fig. 4D) . These results suggest that hypertension reduces the endothelial modulation of phenylephrine responses and that the treatment reestablishes this modulation. The tension developed by the NO synthase antagonist L-NAME (100 mM) after phenylephrine contraction was lower in SHRs when compared with Wistar rats, and this contraction was increased after treatment of SHRs with the anti-TLR4 antibody (Fig. 4E) . These results indirectly suggest that treatment significantly increases NO production. Altogether, these results allow us to propose that the anti-TLR4 antibody treatment improves endothelial dysfunction in SHRs, and this improvement most likely occurs by increasing NO bioavailability.
TLR4 inhibition decreases the contribution of oxidative stress to the vasoconstrictor and vasodilator responses in aortas from hypertensive rats
Endothelial dysfunction accompanying hypertension is frequently associated with reduction in NO bioavailability caused by increased ROS production, among other mechanisms. Therefore, we analyzed the effect of anti-TLR4 antibody treatment on the contribution of ROS to vascular function. The superoxide anion scavenger tiron, the NAD(P)H oxidase inhibitor apocynin and the hydrogen peroxide detoxificant catalase did not affect phenylephrine-induced contraction in Wistar rats, while the three drugs reduced those responses in SHRs (Fig. 5A-C) . Treatment with the anti-TLR4 antibody completely abolished the inhibitory effect of the three antioxidants analyzed (Fig. 5A-C) .
On the other hand, tiron, apocynin and catalase did not affect acetylcholine-induced relaxation in Wistar rats but increased that response in SHRs; after anti-TLR4 antibody treatment of SHRs the enhancing effect of the three compounds was abolished (Fig. 6A-C) . Altogether, these results suggest that TLR4 increased oxidative stress and this would contribute to the impaired vascular function observed in aortas from hypertensive rats. In an attempt to investigate if these effects of TLR4 are related to the increased RAS activity in SHRs, the following experiments were carried out using cultured VSMCs stimulated with Ang II.
Angiotensin II increases oxidative stress in VSMCs through TLR4 activation
In SHR VSMCs, Ang II (100 nM) incubation increased TLR4 mRNA levels from 15 min to 3 h (Fig. 7A) , and this effect was reduced by preincubation with losartan (1 mM, Fig. 7B) , which indicates the involvement of AT 1 receptors in such induction.
It has been widely shown that Ang II increases ROS production thus contributing to the inflammatory process associated with hypertension [1, 6, 36] . Accordingly, in SHR VSMCs, Ang II (100 nM, 2 h) treatment increased NOX-1 and NOX-4 mRNA levels, while p22phox mRNA levels were unaffected (Fig. 8A) ; NOX-2 mRNA levels were scarcely detected (results not shown). In addition, Ang II also increased NAD(P)H oxidase activity and the subsequent superoxide anion production (Fig. 8B, C) . The TLR4 antagonist CLI-095 did not affect NOX-1 mRNA levels; however, CLI-095 mitigated the increased NOX-4 mRNA levels, NAD(P)H activity and superoxide anion production induced by Ang II (Fig. 8A-C) , which indicates a role for TLR4 in the increased oxidative stress induced by Ang II.
The ability of Ang II to induce cell migration and proliferation is well known [37] . The TLR4 inhibitor CLI-095 also reduced the increased cell migration and proliferation induced by Ang II (100 nM, 24 h, Fig. 9A, B) , which suggests that TLR4 contributes to these effects.
In SHR VSMCs, the TLR4 antagonist CLI-095 alone did not modify any parameter studied (results not shown).
Discussion
The results of this study suggest that increased expression of TLR4, which is associated with increased RAS activity, contributes to the occurrence of hypertension. Additionally, this increased TLR4 expression is also involved in the previously described increased oxidative stress that most likely contributes to the endothelial dysfunction observed in hypertension.
TLR4 is expressed on the surface of different cell types including endothelial cells and VSMCs, and is involved in the recognition of and response to LPS, although many non-infectious endogenous TLR4 ligands also exist [4, 20, 21] . There is evidence regarding a role for the TLR4 signaling pathway and the innate immune response in the development of cardiovascular pathologies with an inflammatory component such as atherosclerosis [14] , diabetes [26] [27] [28] and pre-eclampsia [29, 30] . Hypertension has also been considered as a low-grade inflammatory disease, and growing evidence shows that the immune system is involved in the pathophysiology of hypertension [2] [3] [4] . In the present study, we found that TLR4 expression was increased in the three layers of the vascular wall of aortic segments as well as in cultured VSMCs from SHRs compared with Wistar rats, suggesting that TLR4 from the endothelial and smooth muscle cells, and even from the adventitia, might contribute to the effects discussed below. The results are similar to that found in mesenteric resistance arteries from SHR [32] as well as in cardiomyocytes from both adults SHR and L-NAME-induced hypertensive rats [31] . Additionally, in peripheral monocytes from nondiabetic hypertensive patients, increased TLR4 gene expression has also been reported; antihypertensive treatment reduces that expression with a significantly association with the systolic and diastolic blood pressure reduction [38] . Increased TLR4 levels in SHRs can explain the enhanced vascular responses to LPS that we previously observed [7] [8] [9] . Furthermore, TLR4 expression seems to be associated with the development/maintenance of hypertension because treatment of SHRs with an anti-TLR4 antibody for 2 weeks reduced blood pressure, as previously described [32] . Accordingly, a recent report has shown that L-NAME failed to induce hypertension in TLR4 2/2 mice [33] . Moreover, after the use of a neutralizing antibody in vivo in SHRs, the heart rate was also reduced suggesting that the cardiac effects of TLR4 can contribute to the hypertensive action of this pathway. In this sense, it has been described that activation of the TLR4 in the brainstem via AT1R contributes to the sympathoexcitation drive in heart failure [39] and recently Dange et al. [40] has shown that brain TLR4 blockade improves cardiac function in Ang II-induced hypertensive rats.
RAS contributes to the vascular alterations associated with hypertension via its proinflammatory activity in the vascular wall, including the production of ROS, cytokines and prostanoids [1, 6, 36] . Furthermore, Ang II is able to induce the inflammatory response via the TLR4 pathway [13] [14] [15] [16] [17] [18] [19] ; in addition, AT 1 receptor blockers (ARBs) reduce the LPS-induced innnate immune response [41] [42] [43] and protect against myocardial ischemia-reperfusion injury through the TLR4/NF-kB signaling pathway [44] . Accordingly, we found that Ang II increased TLR4 mRNA levels in SHR VSMCs via the AT 1 receptors, and treatment of SHRs with losartan in vivo decreased the increased TLR4 levels found in this strain. These results suggest that the increased RAS activity observed in hypertension contributes to the increased TLR4 levels.
Hypertension is associated with functional vascular alterations such as endothelial dysfunction with impaired endotheliumdependent relaxations and increased vasoconstrictor responses. Endothelial dysfunction is a prognostic factor for cardiovascular events in patients with essential hypertension [45] . Our results demonstrate that the anti-TLR4 antibody treatment improved the vasodilator responses to acetylcholine in SHRs. Additionally, the anti-TLR4 antibody reduced vasoconstrictor responses to phenylephrine, in agreement with results obtained in mesenteric resistance arteries [32] . Moreover, the increased phenylephrine response after endothelial denudation was greater in anti-TLR4 antibody-treated SHRs. Altogether, this study suggests for the first time, to the best of our knowledge, that TLR4 contributes to the endothelial dysfunction observed in hypertension. In keeping with this, our group and others have previously shown that LPS administration induces endothelial dysfunction in both peripheral [46, 47] and cerebral arteries [9] . Additionally, Liang et al. [48] reported that the in vivo and in vitro administration of LPS causes endothelial dysfunction in the arteries of wild-type mice, but not those of TLR4-mutated mice. The proposed role of TLR4 in endothelial dysfunction and the above mentioned increased TLR4 expression found in hypertensive animals can explain the greater impairment of bradykinin-induced relaxation elicited by LPS that was observed in the middle cerebral arteries of hypertensive rats [9] .
One of the mechanisms that explain the endothelial dysfunction induced by TLR4 activation is the reduction of NO contribution to vascular responses. Accordingly, anti-TLR4 treatment improved endothelium-dependent relaxation, which in aorta is dependent on NO [49] ; in addition, the L-NAME-induced contraction was greater in SHR aortic segments after anti-TLR4 antibody treatment, suggesting that this treatment might increase NO bioavailability. Augmented oxidative stress is one of the most generally accepted mechanism to explain the reduced NO bioavailability in hypertension [50, 51] . There is evidence indicating that upon TLR4 activation, LPS increases the generation of ROS, such as O 2 2 and H 2 O 2 , from NAD(P)H oxidase, and these ROS are involved in NF-kB activation and the subsequent expression of proinflammatory cytokines [22] [23] [24] [25] . In the present study we found that the effect of antioxidants (apocynin, catalase and tiron) on both vascular contraction and relaxation disappeared after anti-TLR4 antibody treatment, suggesting that TLR4 contributes to the increased ROS production and endothelial dysfunction observed in hypertension. Accordingly, in obesity-and diabetes-associated endothelial dysfunction by increasing oxidative stress TLR4 plays a key role [48] . Recently, it was proposed that the greater ROS production caused by DAMPs release in L-NAME-induced hypertensive mice contributes to the vascular alterations found in this model [33] . TLR4 could also contribute to endothelial dysfunction by reducing NO production. Indeed, in cardiac microvascular endothelial cells, a reduction of eNOS expression and NO production via TLR4 signaling has been described under hypoxia/reoxygenation conditions [52] . However, we cannot discard COX-dependent mechanisms associated with TLR4 activation that might contribute to the vascular dysfunction associated with hypertension [32] . RAS plays an important role in increasing the oxidative stress present in hypertension [1, 5, 6, 12, 36] . In SHR VSMCs, the TLR4 antagonist mitigated the increased NOX-4 expression, NAD(P)H oxidase activity and superoxide anion production induced by Ang II. These results support the contribution of RAS-induced TLR4 in the oxidative stress observed in hypertension. Some authors have also described the role of TLR4 in the Ang II effects mediated by ROS production. Thus, after Ang II release, osteocalcin activates PKC/TLR4/ROS/COX-2, which mediates the transformation of fibroblasts to myofibroblasts [19] . Additionally, TLR4/MyD88-mediated oxidative stress is involved in Ang II-induced mesangial cell apoptosis [17] .
Ang II induces VSMC proliferation and migration that contribute to the progression of many vascular diseases, including hypertension [37] . Yuen et al. [19] have shown that the Ang IIinduced migration of rat adventitial fibroblasts is mediated by TLR4 activation. Additionally, TLR4 contributes to the increased proliferation and migration induced by other stimuli [53, 54] . Accordingly, the increased cell proliferation and migration induced by Ang II was reversed by TLR4 antagonists, thus suggesting that increased TLR4 expression is functionally associated with structural alterations that can also contribute to hypertension.
In conclusion, this study demonstrates, for the first time, that the increased RAS activity observed in hypertension stimulates the TLR4 pathway, contributing to the occurrence of hypertension. Additionally, by inducing oxidative stress, TLR4 leads to the endothelial dysfunction that is characteristic of this pathology. In recent years, several studies had demonstrated the role of adaptive immunity in the pathogenesis of hypertension [2, 3] . Our results also suggest the impact of the TLR4 signaling pathway on the development of this inflammatory pathology and its associated vascular alterations. However, further investigations that deeply analyze the role of immunity in hypertension and end-organ damage will help develop therapies for this global disease.
